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ABSTRACT
Objectives: Intravenous drug use accounts for most of the new hepatitis C infections world-
wide. Although there is an urgent need for antiviral treatment of infected intravenous drug 
users (IDUs), several factors compromise their treatment including lack of treatment adher-
ence and high dropout rate. The aim of this study was to compare antiviral treatment-related 
problems among former IDUs to HCV-infected patients without a history of IDU. Methods: 
This was a retrospective chart review of HCV-infected IDUs who received combined antiviral 
therapy at the Hepatology Outpatient Clinic of Szent László Hospital between 1 January 2006 
and 31 December 2008. A control group of interferon treated patients with no history of IDU 
matched for age and sex was selected. Results: Dropout rate was significantly higher in the IDU 
group (p = 0.016). Treatment response at the 12th week of treatment was significantly better 
in the IDU group (p = 0.004). Significantly more IDUs underwent antiviral treatment while in 
prison (p = 0.008). Conclusions: In this study higher dropout rate was found among IDUs. IDUs 
had a better response rate to antiviral therapy compared to controls. More attention should be 
paid to factors that worsen treatment adherence of IDUs - particularly lack of abstinence - in 
order to increase the effectiveness of antiviral therapy. 
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INTRODUCTION
In several European countries the preva-
lence of hepatitis C virus (HCV) infection 
in intravenous drug users (IDUs) is above 
70%.1-3 In Hungary until 2006 only limited 
data from health service providers were 
available.4-6 Hungarian surveys reported 10-
30% HCV prevalence rates in IDUs. Start-
ing in 2006, the annual screening of IDUs 
covering specialized outpatient clinics and 
needle/syringe programs (NSP) using ‘dried 
blood spot’ techniques yielded a national 
prevalence of about 25%, though in Buda-
pest the prevalence was considerably higher, 
36% and in one NSP it even reached 70%.7
The most effective current therapy of 
HCV infection is pegylated interferon and 
ribavirin combination that could achieve 
sustained treatment response in 50-60% of 
the cases.8,9 There is no generally accepted 
recommendation concerning the antiviral 
treatment of active IDUs. Some authors ar-
gue that active IDU is a contraindication 
for combination therapy, partly due to their 
poor treatment adherence and partly to the 
increased likelihood of re-infection.10 Oth-
ers regard treatment necessary for harm-re-
duction and preventing further spreading of 
infection.11 There is growing evidence that 
even in active IDUs the benefit of antiviral 
treatment exceeds the risks of side effects 
and re-infection.12 Both active and former 
IDUs have a significantly higher dropout 
rate compared to HCV-infected patients 
without a history of illicit drug use.13,14 In 
Budapest, the Hepatology Outpatient Clinic 
of Szent László Hospital plays a key role in 
the examination and antiviral treatment of 
HCV positive IDUs. 
The aim of this study was to compare 
antiviral treatment-related problems among 
HCV-infected patients with and without a 
history of illicit drug use in the period be-
tween 2006 and 2008.
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METHODS
This was a retrospective chart review of HCV-infected IDUs 
who received combined antiviral therapy at the Hepatol-
ogy Outpatient Clinic of Szent László Hospital between 1 
January 2006 and 31 December 2008. A control group of 
interferon-treated patients without a history of drug use 
matched for age and sex was selected. The following treat-
ment outcomes were analyzed: HCV-PCR results, dropout 
rate, treatment response, and psychiatric complications. 
The percentage of patients receiving antiviral therapy while 
in prison was also recorded. 
For statistical analysis the SPSS 10.0 package (Statistical 
Package for Social Sciences, Chicago, IL, USA) was used. 
Descriptive data were presented with means and standard 
deviations. Binomial data were compared with the chi-
square test; if the value in a cell was less than five, the Fisher 
exact test was applied. Statistical significance was set at 0.05. 
RESULTS 
Of the 6,759 patients who attended the Hepatology Outpa-
tient Clinic between 1 January 2006 and 31 December 2008, 
123 had a history of IDU and 36 of them (28%; 29 men and 
7 women) received antiviral treatment for chronic hepati-
tis C. The mean ages of the sample and the control group 
were 34.44 ± 8.85 and 34.56 ± 8.85, respectively. Ten of the 
36 IDUs dropped out during treatment (Table 1). Table 2 
shows the comparison between IDUs and controls with re-
spect to treatment. Two IDU patients were on methadone 
maintenance, another two on buprenorphin+naloxon main-
tenance while undergoing antiviral treatment; none of 
these four IDUs dropped out. Abstinence was ascertained 
in 7 of the 36 IDU subjects by psychiatric evaluation. An-
other five cases were assessed by a psychiatrist (GG) to 
monitor their ongoing psychiatric treatment or to treat the 
side effects due to the antiviral therapy.
IFN treatment in former IDUs
Table 1. Reasons for termination of antiviral therapy in intravenous drug users
Case Sex  Age Time of termination   HCV-PCR Reason for termination of therapy 
    3rd month
1 Male 26 1st month   THC+IF- induced psychosis   
     (hospitalization)
2 Male 43 1st month  Thrombopenia
3  Male 27 7st month  Unknown. Released from prison? 
4 Male 26 3rd month   Disappeared. Released from prison?
5  Female 51 8th month Negative Hypothyreosis
6 Male 19 6th month Negative Disappeared (side effects: itching,  
     loss of appetite)
7 Male 29 7th month  Disappeared. Released?
8 Male 41 1st month  Disappeared. Released from prison?  
     Psychiatric condition deteriorated?
9 Male 40 8th month   Refused to continue. 
     Released from prison?
10 Female 34 9th month Negative Diffuse pain, weight loss, indigestion.
Table 2. Comparison of the outcome of combined antiviral therapy between intravenous drug users and controls  
 IDUs Control group Statistics 
HCV-PCR at 12th week 28 29 p = 1.000
Negative HCV-PCR at 12th week  18 9 p = 0.004 
Negative HCV-PCR at 24th week  22 17 p = 0.125
Rapid responder 2 1 p = 1.000
Prolonged therapy 1 4 p = 0.250
Dropout   10 3 p = 0.016 
Termination due to ineffectiveness 3 8 p = 0.063
Therapy while in prison  10 2 p = 0.008 
Psychiatric complications  5 8 p = 0.250
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DISCUSSION
It is estimated that there are at least 2000 IDUs in Bu-
dapest,15 and at least 700 of them could be infected with 
HCV. Yet, only 123 (18%) sought treatment in these 
three years at the Hepatology Outpatient Clinic of Szent 
László Hospital. This low proportion clearly indicates 
the need for increasing the efforts to better identify 
HCV-infected IDUs, a rather difficult task.16 
In this study, IDU patients prematurely terminated 
treatment more frequently (p = 0.016) than the con-
trol group; in three cases due to somatic and in one 
due to psychiatric complications (Table 1). Five pa-
tients dropped out for unknown reasons; four received 
antiviral combination therapy while in prison, while 
the fifth patient reported itching and loss of appetite. 
Similar dropout rate (31%) was found by Seal et al.,17 
and the corresponding figure was even higher (43%) in 
a German report13 than the 28% seen in this study. A 
possible explanation for the lower dropout rate could 
be that in our hepatology center only 28% of the HCV-
infected IDU patients received antiviral treatment, 
as opposed to 89% in Schaefer et al’s study which in-
cluded non-IDU patients as well. All four patients in 
substitution therapy adhered to treatment and three 
became HCV-PCR negative by week 12. By the end 
of the study period, however, only one completed the 
treatment successfully. 
In the group of IDUs, 50% and 63% became HCV-
PCR negative by the 12th and 24th week, respectively. 
At the 12th week the IDU group showed significantly 
better response to treatment than the control group 
(p = 0.004) indicating a more rapid treatment response 
by IDUs; however, this difference disappeared by the 
24th week. IDUs’ better antiviral treatment response is 
also supported by the finding that fewer cases of IDUs 
needed prolonged (up to 18 months) treatment and rap-
id response was more frequent, though these differences 
did not reach statistical significance. 
The response rate of IDUs at week 24 in this study 
was rather high (63% were HCV-PCR negative) in com-
parison to other studies.13,18 This could be explained by 
the possibility of having more frequent genotypes 2 and 
3 in the sample of IDUs,19 as patients with these two gen-
otypes respond better to antiviral treatment than geno-
types 1 and 4.20
The need for psychiatric evaluation were signifi-
cantly more often13 in the group of IDUs, although the 
evaluation mainly aimed at confirming abstinence. 
Serious psychiatric problems resulting in termination 
of treatment were restricted to the IDU group. In one 
case, tetrahydrocannabinol (THC) abuse during anti-
viral therapy led to psychosis; another patient who had 
been on psychiatric treatment discontinued antiviral 
therapy after one month. Schaefer et al.13 found simi-
lar reasons for treatment termination among IDUs. 
Though psychiatric complications were observed 
slightly more frequently in the control group compared 
to IDUs (8 vs. 5), psychiatric evaluation was requested 
for only one case and no patient dropped out from in-
terferon therapy because of psychiatric reasons. In four 
cases the treating physicians recommended short-term 
anxiolytic treatment. 
The results of this study should be interpreted with 
caution due to the relatively small sample size and the 
inaccuracies inherent to retrospective chart reviews.
CONCLUSION
In this study, higher dropout rate was found among IDUs 
who otherwise had a better response to antiviral therapy 
compared to controls. More attention should be paid to fac-
tors that worsen treatment adherence of IDUs – particularly 
lack of abstinence – in order to increase the effectiveness of 
antiviral therapy. 
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